Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

(2020) Juan Pablo Frias et al.   DIABETES OBESITY & METABOLISM

Dose‐dependent reduction in body weight with LIK066 treatment in Japanese patients with obesity

(2020) Koutaro Yokote et al.   DIABETES OBESITY & METABOLISM

Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

(2020) Lin Liu et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results

(2020) K.J. Lucas et al.   DIGESTIVE AND LIVER DISEASE

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

(2020) Eugene Han et al.   Journal of Clinical Medicine

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

(2020) Mark L. Hartman et al.   DIABETES CARE

1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice

(2020) JAEHYUK CHOI et al.   DIABETES

Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals

(2019) Lærke S. Gasbjerg et al.   DIABETES

The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC

(2019) Michael Trauner et al.   HEPATOLOGY

The Regulation of Peripheral Metabolism by Gut-Derived Hormones

(2019) Emily W. L. Sun et al.   Frontiers in Endocrinology

Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis

(2019) Mei Zhou et al.   JOURNAL OF LIPID RESEARCH

NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

(2019) Stephen A. Harrison et al.   HEPATOLOGY

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

(2019) Lee-Lee Lai et al.   DIGESTIVE DISEASES AND SCIENCES

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes

(2019) Yan‐Ling He et al.   DIABETES OBESITY & METABOLISM

FGF19 Analogue as a Surgical Factor Mimetic that Contributes to Metabolic Effects Beyond Glucose Homeostasis

(2019) Alex M. DePaoli et al.   DIABETES

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

(2019) Satoshi Ida et al.   Cardiovascular Diabetology

Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies

(2019) Jie Liu et al.   Diabetes & Vascular Disease Research

PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease

(2019) Roberto Calle et al.   JOURNAL OF HEPATOLOGY

LBP-29-BIO89-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys

(2019) Moti Rosenstock et al.   JOURNAL OF HEPATOLOGY

PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects

(2019) Alex DePaoli et al.   JOURNAL OF HEPATOLOGY

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

(2019) Philip Newsome et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

(2019) Upendra Kaul et al.   Cardiovascular Diabetology

982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects

(2019) JAE DUK CHOI et al.   DIABETES

140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

(2019) ALEX DEPAOLI et al.   DIABETES

The incretin system in healthy humans: The role of GIP and GLP-1

(2019) Jens Juul Holst   METABOLISM-CLINICAL AND EXPERIMENTAL

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study

(2019) Clara Depommier et al.   NATURE MEDICINE

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

(2019) Sabine Kahl et al.   DIABETES CARE

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development

(2019) Juliette Mouries et al.   JOURNAL OF HEPATOLOGY

First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities

(2019) Majid M. Syed‐Abdul et al.   HEPATOLOGY

Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist

(2019) Victoria E R Parker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

(2019) Amalia Gastaldelli et al.   DIABETES OBESITY & METABOLISM

Increased liver localization of lipopolysaccharides in human and experimental non‐alcoholic fatty liver disease

(2019) Guido Carpino et al.   HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Marked differences in tight junction composition and macromolecular permeability among different intestinal cell types

(2018) Sarah C. Pearce et al.   BMC BIOLOGY

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice

(2018) Dustin M. Lee et al.   Cardiovascular Diabetology

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

(2018) Eric J. Lawitz et al.   Clinical Gastroenterology and Hepatology

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

(2018) Fernando Bril et al.   Clinical Gastroenterology and Hepatology

Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model

(2018) IN YOUNG CHOI et al.   DIABETES

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

(2018) K. Cusi et al.   DIABETIC MEDICINE

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

(2018) Jan W. Eriksson et al.   DIABETOLOGIA

MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis

(2018) Jerry R. Colca et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Human gut microbiome: hopes, threats and promises

(2018) Patrice D Cani   GUT

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

(2018) Jasmohan S. Bajaj et al.   HEPATOLOGY

Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease

(2018) Francesca Romana Ponziani et al.   HEPATOLOGY

Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism

(2018) Preeti Pathak et al.   HEPATOLOGY

Lipotoxicity and the gut-liver axis in NASH pathogenesis

(2018) Fabio Marra et al.   JOURNAL OF HEPATOLOGY

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate

(2018) Benaïssa Boubia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

(2018) Boyu Li et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

(2018) Philip Ambery et al.   LANCET

Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women

(2018) Lesley Hoyles et al.   NATURE MEDICINE

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut hormone polyagonists for the treatment of type 2 diabetes

(2018) Sara J. Brandt et al.   PEPTIDES

Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection

(2018) Christoph A. Thaiss et al.   SCIENCE

Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review

(2018) Katia P. Souto et al.   Surgery for Obesity and Related Diseases

Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study

(2018) Paul Chi Ho Lee et al.   Diabetes Therapy

Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study

(2018) Paul Chi Ho Lee et al.   Diabetes Therapy

Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT

(2018) Jotham Suez et al.   CELL

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials

(2018) Joachim Tillner et al.   DIABETES OBESITY & METABOLISM

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study

(2018) Niina Matikainen et al.   DIABETES OBESITY & METABOLISM

Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease

(2018) Huikuan Chu et al.   GUT

Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

(2018) Zobair Younossi et al.   HEPATOLOGY

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)

(2018) Yoshio Sumida et al.   HEPATOLOGY RESEARCH

Lixisenatide reduces chylomicron triacylglycerol due to increased clearance

(2018) Martin B Whyte et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Peptide-based multi-agonists: a new paradigm in metabolic pharmacology

(2018) Sara J. Brandt et al.   JOURNAL OF INTERNAL MEDICINE

Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction

(2018) Chunwei Cheng et al.   LIFE SCIENCES

The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health

(2018) Marta Olivares et al.   Frontiers in Microbiology

Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease

(2018) Teruki Miyake et al.   Open Medicine

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

(2018) Kenneth Cusi et al.   DIABETES OBESITY & METABOLISM

Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD

(2018) Jinhua Yan et al.   HEPATOLOGY

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

(2018) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

(2018) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

(2018) Edgar D. Charles et al.   Obesity

Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease

(2018) Mitsuko Inoue et al.   Journal of Diabetes Investigation

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

(2018) Marta Seghieri et al.   Frontiers in Endocrinology

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

(2018) Yuya Seko et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease

(2017) Malek Yaghoubi et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats

(2017) Qian Zhang et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes

(2017) Akio Ohta et al.   EXPERT OPINION ON PHARMACOTHERAPY

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

(2017) Michael Trauner et al.   HEPATOLOGY

A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice

(2017) M. Pilar Valdecantos et al.   HEPATOLOGY

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

(2017) Puneet Puri et al.   HEPATOLOGY

Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis

(2017) J. Skarbaliene et al.   JOURNAL OF HEPATOLOGY

Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15

(2017) Mei Zhou et al.   JOURNAL OF HEPATOLOGY

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

(2017) Auvro R. Mridha et al.   JOURNAL OF HEPATOLOGY

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

(2017) Yong-ho Lee et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

(2017) David C. Tully et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis

(2017) Wei Jia et al.   Nature Reviews Gastroenterology & Hepatology

Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity

(2017) Daniele Seo et al.   NUCLEAR MEDICINE AND BIOLOGY

Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats

(2017) Qian Zhang et al.   PLoS One

The Human Gut Microbiome in Liver Diseases

(2017) Brian Davis et al.   SEMINARS IN LIVER DISEASE

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

(2017) Giovanna Muscogiuri et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

(2017) Tisha R Joy et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus

(2017) Cristina Llorente et al.   Nature Communications

Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis

(2017) Mei Zhou et al.   Nature Communications

Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2017) Yajie Dong et al.   Clinics and Research in Hepatology and Gastroenterology

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease

(2017) Wenhuan Feng et al.   Journal of Diabetes

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

(2017) Sigrid Jall et al.   Molecular Metabolism

Metformin Improves Ileal Epithelial Barrier Function in Interleukin-10 Deficient Mice

(2017) Yansong Xue et al.   PLoS One

Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD

(2017) Irene Pierantonelli et al.   Scientific Reports

Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling

(2016) Zi-yu Zhou et al.   ACTA PHARMACOLOGICA SINICA

Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction

(2016) Antje Damms-Machado et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats

(2016) Jin-Hang Gao et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors

(2016) Takamasa Ohki et al.   CLINICAL DRUG INVESTIGATION

Clinical Diabetes/Therapeutics

(2016)   DIABETES

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

(2016) L.A. Leiter et al.   DIABETES & METABOLISM

Metformin Is Associated With Higher Relative Abundance of Mucin-DegradingAkkermansia muciniphilaand Several Short-Chain Fatty Acid–Producing Microbiota in the Gut

(2016) Jacobo de la Cuesta-Zuluaga et al.   DIABETES CARE

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

(2016) S. J. Henderson et al.   DIABETES OBESITY & METABOLISM

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

(2016) Mark M. Smits et al.   DIABETOLOGIA

Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3–36

(2016) Eva W Iepsen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity

(2016) Pierre Bedossa et al.   GUT

Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

(2016) Amalia Gastaldelli et al.   HEPATOLOGY

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach

(2016) Federica Del Chierico et al.   HEPATOLOGY

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

(2016) Jérôme Boursier et al.   HEPATOLOGY

Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus

(2016) Yuya Seko et al.   HEPATOLOGY RESEARCH

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

(2016) Yuya Seko et al.   HEPATOLOGY RESEARCH

Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis

(2016) Guoxiang Xie et al.   INTERNATIONAL JOURNAL OF CANCER

Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study

(2016) Jean-Michel Petit et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intra-islet glucagon-like peptide 1

(2016) Genevieve E. Fava et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

(2016) Matthew J. Armstrong et al.   JOURNAL OF HEPATOLOGY

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

(2016) Jeffrey Cui et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice

(2016) Hubert Plovier et al.   NATURE MEDICINE

The role of the gut microbiota in NAFLD

(2016) Christopher Leung et al.   Nature Reviews Gastroenterology & Hepatology

Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease

(2016) Claudia Fuchs et al.   SEMINARS IN LIVER DISEASE

Distinctly altered gut microbiota in the progression of liver disease

(2016) Guoxiang Xie et al.   Oncotarget

Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study

(2016) Xinfeng Yan et al.   Journal of Diabetes Research

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

(2016) Michael A Nauck et al.   Lancet Diabetes & Endocrinology

Non-alcoholic fatty liver and the gut microbiota

(2016) Stavros Bashiardes et al.   Molecular Metabolism

Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System

(2015) Giuseppe Daniele et al.   DIABETES

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

(2015) An Tang et al.   DIABETES CARE

Bile Acids as Hormones: The FXR-FGF15/19 Pathway

(2015) Steven A. Kliewer et al.   DIGESTIVE DISEASES

Akkermansia muciniphilaand improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology

(2015) Maria Carlota Dao et al.   GUT

Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease

(2015) Norelle R. Reilly et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

(2015) Sungsoon Fang et al.   NATURE MEDICINE

Gut biogeography of the bacterial microbiota

(2015) Gregory P. Donaldson et al.   NATURE REVIEWS MICROBIOLOGY

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

(2015) Changtao Jiang et al.   Nature Communications

How Inflammation Impinges on NAFLD: A Role for Kupffer Cells

(2015) Nádia Duarte et al.   Biomed Research International

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

(2014) Yan Bi et al.   ACTA DIABETOLOGICA

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

(2014) Hui Fan et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

(2014) M. Zhou et al.   CANCER RESEARCH

The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease

(2014) Rifaat Safadi et al.   Clinical Gastroenterology and Hepatology

Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?

(2014) Alex M. DePaoli et al.   DIABETES CARE

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

(2014) T. Heise et al.   DIABETES OBESITY & METABOLISM

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity

(2014) Valentina Giorgio et al.   DIGESTIVE AND LIVER DISEASE

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation

(2014) Chiara Degirolamo et al.   HEPATOLOGY

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)

(2014) Yuichiro Eguchi et al.   HEPATOLOGY RESEARCH

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

NLRP3 inflammasome activation is required for fibrosis development in NAFLD

(2014) Alexander Wree et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH

(2014) Samuele De Minicis et al.   PLoS One

Regionally Distinct Alterations in the Composition of the Gut Microbiota in Rats with Streptozotocin-Induced Diabetes

(2014) Roland Wirth et al.   PLoS One

Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity

(2014) Sophie Leclercq et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease

(2014) Kouichi Miura   WORLD JOURNAL OF GASTROENTEROLOGY

Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study

(2014) Takahiro Watanabe et al.   Journal of Diabetes Investigation

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

(2014) Lise L Gluud et al.   BMJ Open

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

(2014) Norbert Stefan et al.   Lancet Diabetes & Endocrinology

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools

(2014) Rosaria Meli et al.   Frontiers in Immunology

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in Obese Mice Chronically Maintained on an Obesogenic Diet

(2013) C. Clemmensen et al.   DIABETES

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

(2013) K. Hermansen et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Intestinal microbiota in patients with nonalcoholic fatty liver disease

(2013) Marialena Mouzaki et al.   HEPATOLOGY

Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice

(2013) Samuele De Minicis et al.   HEPATOLOGY

Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus

(2013) Daisuke Suzuki et al.   INTERNAL MEDICINE

The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism

(2013) Gijs den Besten et al.   JOURNAL OF LIPID RESEARCH

GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK

(2013) Lili Zhang et al.   LIVER INTERNATIONAL

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

(2013) Shin Yoshimoto et al.   NATURE

Diet rapidly and reproducibly alters the human gut microbiome

(2013) Lawrence A. David et al.   NATURE

The gut microbiota — masters of host development and physiology

(2013) Felix Sommer et al.   NATURE REVIEWS MICROBIOLOGY

Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

(2013) Michael Grimm et al.   POSTGRADUATE MEDICINE

Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients

(2013) Kristina Blaslov et al.   Clinics and Research in Hepatology and Gastroenterology

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program

(2012) M. J. Armstrong et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis

(2012) Nitika A. Gupta et al.   AMERICAN JOURNAL OF PATHOLOGY

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

(2012) Jonathan W. Day et al.   BIOPOLYMERS

Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

(2012) Seiki Miura et al.   BMC CANCER

Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4

(2012) Dianne H. Dapito et al.   CANCER CELL

Intestinal Permeability and Its Regulation by Zonulin: Diagnostic and Therapeutic Implications

(2012) Alessio Fasano   Clinical Gastroenterology and Hepatology

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

(2012) R. M. Bergenstal et al.   DIABETES OBESITY & METABOLISM

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

(2012) M. Nauck et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

Direct effect of GLP-1 infusion on endogenous glucose production in humans

(2012) M. Seghieri et al.   DIABETOLOGIA

Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)

(2012) Valentina Volynets et al.   DIGESTIVE DISEASES AND SCIENCES

Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome

(2012) Anne Vrieze et al.   GASTROENTEROLOGY

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

(2012) Lixin Zhu et al.   HEPATOLOGY

Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis

(2012) Anne Leroux et al.   JOURNAL OF HEPATOLOGY

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Structure, function and diversity of the healthy human microbiome

(2012)   NATURE

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

(2012) Jorge Henao-Mejia et al.   NATURE

The role of the gut microbiota in nutrition and health

(2012) Harry J. Flint et al.   Nature Reviews Gastroenterology & Hepatology

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(2012) Daniel J. Cuthbertson et al.   PLoS One

GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice

(2012) Edwin T. Parlevliet et al.   PLoS One

Host-Gut Microbiota Metabolic Interactions

(2012) J. K. Nicholson et al.   SCIENCE

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

(2012) Takamasa Ohki et al.   TheScientificWorldJOURNAL

Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice

(2011) Timea Csak et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice

(2011) J. Shirakawa et al.   DIABETES

Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2

(2011) G. Tolhurst et al.   DIABETES

Effects of Exenatide on Measures of  -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

(2011) M. C. Bunck et al.   DIABETES CARE

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

(2011) S. L. Samson et al.   DIABETOLOGIA

Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection

(2011) Netanya G. Sandler et al.   GASTROENTEROLOGY

Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects

(2011) E. Cersosimo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lipotoxicity in NASH

(2011) Michael Fuchs et al.   JOURNAL OF HEPATOLOGY

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism

(2011) Masayuki Miyazaki   Molecular Medicine Reports

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

(2011) Bolormaa Vandanmagsar et al.   NATURE MEDICINE

Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes

(2011) Padma Sathyanarayana et al.   Obesity

GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy

(2011) Shvetank Sharma et al.   PLoS One

Inflammasome is a central player in the induction of obesity and insulin resistance

(2011) R. Stienstra et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series

(2010) Patrick R Kenny et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

(2010) Eric A. Schwartz et al.   ATHEROSCLEROSIS

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans

(2010) M. Asmar et al.   DIABETES

Effects of Exenatide Plus Rosiglitazone on  -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

(2010) R. A. DeFronzo et al.   DIABETES CARE

Molecular mechanisms underlying nutrient-stimulated incretin secretion

(2010) Helen E. Parker et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice

(2010) Kouichi Miura et al.   GASTROENTEROLOGY

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents

(2010) Le-Xing Yu et al.   HEPATOLOGY

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis

(2010) Md. Hasan Zaki et al.   IMMUNITY

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

(2010) Renata Belfort et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

(2010) Gábor Firneisz et al.   PLoS One

Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts

(2009) Peter Fickert et al.   AMERICAN JOURNAL OF PATHOLOGY

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

(2009) A. Pocai et al.   DIABETES

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

(2009) Luca Miele et al.   HEPATOLOGY

Comparable effects of moderate intensity exercise on changes in anorectic gut hormone levels and energy intake to high intensity exercise

(2009) Shin-ya Ueda et al.   JOURNAL OF ENDOCRINOLOGY

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic Acid (MK-0533): A Novel Selective Peroxisome Proliferator-Activated Receptor γ Modulator for the Treatment of Type 2 Diabetes Mellitus with a Reduced Potential to Increase Plasma and Extracellular Fluid Volume

(2009) John J. Acton et al.   JOURNAL OF MEDICINAL CHEMISTRY

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog

(2009) K. Machida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice

(2008) P. D. Cani et al.   DIABETES

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

(2008) C. Fernández-Miranda et al.   DIGESTIVE AND LIVER DISEASE

Microbes in Gastrointestinal Health and Disease

(2008) Andrew S. Neish   GASTROENTEROLOGY

Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model

(2008) Susan L Samson et al.   MOLECULAR THERAPY

Targeting bile-acid signalling for metabolic diseases

(2008) Charles Thomas et al.   NATURE REVIEWS DRUG DISCOVERY